For instance, FGFR3 fusions dominated in glioma (91.43%) and lung cancer (53.85%), while FGFR1 fusions were only observed in soft tissue sarcoma (Figure 1C and Table S2). This evidence concerns the gene FGFR1 and soft tissue sarcoma.